Research by Professor Wedzicha of the National Heart and Lung Institute (NHLI) discover better mixture and combination therapy for COPD exacerbations Treatment: It is rumination that there are nearly 3 million people in the UK who suffer with chronic obstructive pulmonary disorder, more repeatedly called COPD. Patients are mostly distressed by COPD Exacerbations where they see a unanticipated exacerbate of their symptoms, such as breathlessness, with the capacity to develop or happen in the future triggered by an infection or air pollutants. To combat this, patients are placed on treatment plans to try to manage the prevalence of these intermittence and ultimately reduce their occurrence.
Currently there are two options recommended for prevention of this disease. Either inhaled corticosteroids (ICS) with long acting Beta 2 agonists (LABA), or an inhaled long-acting muscarinic anatagonist (LAMA). To date a combination of the two regimes had not been compared to find the best results for patients.New research by Professor Wedzicha of the National Heart and Lung Institute is the first study to compare two combination therapies to COPD exacerbations Treatment patients at risk of exacerbations.
Comparing two bronchodilators combined (LABA/LAMA) to the standard therapy, that uses a combination of a long acting beta agonist and inhaled corticosteroid – Salmeterol and Fluticasone (ICS/LABA). Findings from the study were published in the New England journal of Medicineearlier this year.The trial showed that Indacaterol/glycopyrronium (LABA/LAMA) was superior to the current recommended COPD exacerbations Treatment for the whole spectrum of exacerbation symptoms tested, with a good safety profile and less episodes of pneumonia. Professor Wedzicha was the PI for the trial and it was sponsored by Novartis.
COPD exacerbations play an important role in this disease management as they affect disease progression, hospital admissions and are costly to healthcare services. The assessment of COPD exacerbations during the trial involved the methodology developed by Prof Wedzicha and her research team and used in the London COPD exacerbation cohort based at Imperial College. The results of this trial will now have major implications for Copd Exacerbations patients and COPD exacerbations Treatment algorithms in guidelines will need to be revised. This should help improve the healthcare and quality of life for COPD patients .